Prostate cancer is the most commonly diagnosed cancer in men and accounts for significant morbidity and
mortality in the western world. While traditional therapies are effective at clearing early stage cancer, they often fail to
treat late stage metastatic disease. Thus, an effective therapy that targets prostate tumor growth and metastasis is desired
for alleviating the disease and improving patient outcomes. Natural extracts have been the focus of recent investigation,
particularly those with reduced cellular toxicity to healthy tissue. In this review, we discuss one potential candidate, ganoderic
acid, an extract from the Ganoderma lucidum mushroom that has been tested in multiple cancer models. Interestingly,
ganoderic acid DM (GA-DM) has shown toxicity to both androgen-dependent and independent prostate cancer cells
with reduced osteoclastogenesis in late stage metastatic disease. This review will discuss the current knowledge on this
GA-DM extract and the potential benefit in treating advanced prostate cancer. We will also provide an overview on the
targeted delivery of GA-DM through nanoparticles that would reduce bystander toxicity and improve the drug’s effectiveness.
An improved understanding of this drug and its uses will advance the field of natural chemotherapeutics, particularly
in treating advanced prostate cancer.